The Vascular Dementias drugs in development market research report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vascular Dementias. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vascular Dementias and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Vascular Dementias by 18 companies/universities/institutes. The top development phase for Vascular Dementias is preclinical with nine drugs in that stage. The Vascular Dementias pipeline has 14 drugs in development by companies and four by universities/ institutes. Some of the companies in the Vascular Dementias pipeline products market are: Max Delbruck Center for Molecular Medicine, Alector and Hemostemix.
The key targets in the Vascular Dementias pipeline products market include Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN), Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7), and cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35).
The key mechanisms of action in the Vascular Dementias pipeline product include Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN) Antagonist with two drugs in Phase III. The Vascular Dementias pipeline products include five routes of administration with the top ROA being Oral and five key molecule types in the Vascular Dementias pipeline products market including Small Molecule, and Cell Therapy.
Vascular Dementias overview
Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or the cingulate gyrus.
For a complete picture of Vascular Dementias’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
